234 research outputs found
Waiting as probation: selecting self-disciplining asylum seekers
This article diagnoses and critiques a type of governmentality associated with waiting during protracted asylum appeal procedures by drawing upon data from a multi-methodological study of asylum adjudication in Europe. Focusing on Austria, Germany and Italy, we explore the use of integration-related considerations in asylum appeal processes by looking at the ways in which these considerations permeate judgesâ decision-making, particularly, but not exclusively, on the granting of national, non-EU harmonised protection statuses. Building on insights from the literature on conditional integration we question the implicit socio-political biases and moral assumptions that underpin this permeation. We show that the use of integration-related considerations in asylum appeals transforms migrant waiting into a period of probation during which rejected asylum seekersâ conducts are governed and tested in relation to the use of time. More than simply waiting patiently, rejected asylum seekers are expected to wait productively, whereby productivity is assessed through the neoliberal imperatives of entrepreneurship, autonomy and self-improvement. We thus contribute to scholarship on migrant waiting by showing how time is capitalised by state authorities even whenâand actually becauseâit offers opportunities for migrants
Waiting as probation: selecting self-disciplining asylum seekers
This is the final version. Available on open access from Taylor and Francis via the DOI in this recordData Availability Statement:
There are no datasets available for this paper.This article diagnoses and critiques a type of governmentality associated with waiting during
protracted asylum appeal procedures by drawing upon data from a multi-methodological study
of asylum adjudication in Europe. Focusing on Austria, Germany and Italy, we explore the use
of integration-related considerations in asylum appeal processes by looking at the ways in
which these considerations permeate judgesâ decision-making, particularly, but not
exclusively, on the granting of national, non-EU harmonised protection statuses. Building on
insights from the literature on conditional integration we question the implicit socio-political
biases and moral assumptions that underpin this permeation. We show that the use of
integration-related considerations in asylum appeals transforms migrant waiting into a period
of probation during which rejected asylum seekersâ conducts are governed and tested in relation
to the use of time. More than simply waiting patiently, rejected asylum seekers are expected to
wait productively, whereby productivity is assessed through the neoliberal imperatives of
entrepreneurship, autonomy and self-improvement. We thus contribute to scholarship on
migrant waiting by moving beyond an emphasis on the contradictory character of waiting, as
both imposition and potentiality, and showing how time is capitalised by state authorities even
when â and actually because â it offers opportunities for migrants
Using multi-member panels to tackle RSD complexities
This is the final version. Available on open access from the Refugee Studies Centre, University of Oxford via the link in this recordEuropean Commissio
Legal geographies of irregular migration : An outlook on immigration detention
In this article, I discuss legal geographies of irregular migration, drawing on a case study on immigration detention in Finland. Based on analysis of detention records, four different types of legal geographies are identified, relating to southânorth movement of thirdâcountry nationals inside Europe, criminalised Eastern European EU citizens, irregularity during the asylum process (in particular, related to the Dublin Regulation) and irregularly residing foreign nationals, including deportable longâterm residents. The analysis focuses on the relations between space, law and persons during detainees' irregular migration trajectories, paying attention to their varying entry routes, residence times, legal grounds for removal and detention and removal countries. I argue for the need for empirically contextualised analysis that addresses the complex relations between law and geography beyond a particular national context, in order to better understand the dynamics of irregular migration in all its variety.In this article, I discuss legal geographies of irregular migration, drawing on a case study on immigration detention in Finland. Based on analysis of detention records, four different types of legal geographies are identified, relating to southânorth movement of thirdâcountry nationals inside Europe, criminalised Eastern European EU citizens, irregularity during the asylum process (in particular, related to the Dublin Regulation) and irregularly residing foreign nationals, including deportable longâterm residents. The analysis focuses on the relations between space, law and persons during detainees' irregular migration trajectories, paying attention to their varying entry routes, residence times, legal grounds for removal and detention and removal countries. I argue for the need for empirically contextualised analysis that addresses the complex relations between law and geography beyond a particular national context, in order to better understand the dynamics of irregular migration in all its variety.Peer reviewe
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies
Recently, treatment of immune-mediated thrombotic thrombocytopenic purpura (ITTP) has changed with the advent of caplacizumab in clinical practice. The International Working Group (IWG) has recently integrated the ADAMTS-13 activity/autoantibody monitoring in consensus outcome definitions. We report three ITTP cases during the coronavirus disease 2019 pandemic, that received a systematic evaluation of ADAMTS-13 activity and autoantibodies. We describe how the introduction of caplacizumab and ADAMTS-13 monitoring could change the management of ITTP patients and discuss whether therapeutic choices should be based on the clinical response alone. ADAMTS-13 activity/antibodies were assessed every 5 days. Responses were evaluated according to updated IWG outcome definitions. These kinetics, rather than clinical remission, guided the therapy, allowing early and safe caplacizumab discontinuation and sensible administration of rituximab. Caplacizumab was cautiously discontinued after achieving ADAMTS-13 complete remission. These cases illustrate that prospective ADAMTS-13 evaluation and use of updated IWG definitions may improve real-life patientsâ management in the caplacizumab era
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62), splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per 100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new antithrombotic drugs and JAK-2 inhibitors
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Background: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the outcome. Methods: A centralized electronic clinical database was created in 20 European hematology centers, including clinical and laboratory data for 524 patients who received ruxolitinib for myelofibrosis. Results: At 3\ua0years, 40.8% of patients had stopped ruxolitinib. Baseline predictors of drug discontinuation were: intermediate-2\u2013risk/high-risk category (Dynamic International Prognostic Score System), a platelet count <100
7109 per liter, transfusion dependency, and unfavorable karyotype. At last contact, 268 patients (51.1%) had discontinued therapy, and the median drug exposure was 17.5\ua0months. Fifty patients (18.7%) died while taking ruxolitinib. The reasons for discontinuation in the remaining 218 patients were the lack (22.9%) or loss (11.9%) of a spleen response, ruxolitinib-related adverse events (27.5%), progression to blast phase (23.4%), ruxolitinib-unrelated adverse events (9.2%), and allogeneic transplantation during response (5.1%). The median survival after ruxolitinib was 13.2\ua0months and was significantly better in the 167 patients who discontinued ruxolitinib in chronic phase (27.5 vs 3.9\ua0months for those who discontinued in blast phase; P\ua0<.001). No survival differences were observed among patients who discontinued ruxolitinib in chronic phase because of lack of response, loss of response, or ruxolitinib-related adverse events. The use of investigational agents and/or ruxolitinib rechallenge were associated with improved outcome. Conclusions: The survival of patients with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can improve outcome, emphasizing the need for novel therapies
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
none36Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosisopenPalandri F.; Palumbo G.A.; Elli E.M.; Polverelli N.; Benevolo G.; Martino B.; Abruzzese E.; Tiribelli M.; Tieghi A.; Latagliata R.; Cavazzini F.; Bergamaschi M.; Binotto G.; Crugnola M.; Isidori A.; Caocci G.; Heidel F.; Pugliese N.; Bosi C.; Bartoletti D.; Auteri G.; Cattaneo D.; Scaffidi L.; Trawinska M.M.; Stella R.; Ciantia F.; Pane F.; Cuneo A.; Krampera M.; Semenzato G.; Lemoli R.M.; Iurlo A.; Vianelli N.; Cavo M.; Breccia M.; Bonifacio M.Palandri, F.; Palumbo, G. A.; Elli, E. M.; Polverelli, N.; Benevolo, G.; Martino, B.; Abruzzese, E.; Tiribelli, M.; Tieghi, A.; Latagliata, R.; Cavazzini, F.; Bergamaschi, M.; Binotto, G.; Crugnola, M.; Isidori, A.; Caocci, G.; Heidel, F.; Pugliese, N.; Bosi, C.; Bartoletti, D.; Auteri, G.; Cattaneo, D.; Scaffidi, L.; Trawinska, M. M.; Stella, R.; Ciantia, F.; Pane, F.; Cuneo, A.; Krampera, M.; Semenzato, G.; Lemoli, R. M.; Iurlo, A.; Vianelli, N.; Cavo, M.; Breccia, M.; Bonifacio, M
- âŠ